
SB 525334
CAS No. 356559-20-1
SB 525334( SB-525334 | SB525334 )
Catalog No. M14224 CAS No. 356559-20-1
SB 525334 is a potent and selective inhibitor of TGF-β1 receptor (ALK5) inhibitor with IC50 of 14,5 nM.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 48 | In Stock |
![]() ![]() |
10MG | 80 | In Stock |
![]() ![]() |
25MG | 160 | In Stock |
![]() ![]() |
50MG | 268 | In Stock |
![]() ![]() |
100MG | 427 | In Stock |
![]() ![]() |
200MG | 502 | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameSB 525334
-
NoteResearch use only, not for human use.
-
Brief DescriptionSB 525334 is a potent and selective inhibitor of TGF-β1 receptor (ALK5) inhibitor with IC50 of 14,5 nM.
-
DescriptionSB 525334 is a potent and selective inhibitor of TGF-β1 receptor (ALK5) inhibitor with IC50 of 14,5 nM, 4-fold less potent against ALK4 and inactive for ALK2, ALK3, and ALK6 (IC50>10 uM); blocks TGFβ1-induced phosphorylation and nuclear translocation of Smad2/3 in renal proximal tubule cells and inhibits TGFβ1-induced increases in PAI-1 and procollagen α1 mRNA expression in A498 renal epithelial carcinoma cells at 1 uM; significantly inhibits PAN-induced proteinuria in rat model of nephritis-induced renal fibrosis.
-
In VitroSB525334 (1 μM; for 15 minutes before stimulating with 0.625 ng/ml of TGF-β1, assesses after 6 days) inhibits TGF-β1-mediated proliferation of familial idiopathic pulmonary arterial hypertension (iPAH) pulmonary artery smooth muscle cells (PASMCs) at an IC50 of 295 nM . Cell Proliferation AssayCell Line:PASMC cells Concentration:1 μM Incubation Time:Pre-incubated for 15 minutes (before stimulating with 0.625 ng/ml of TGF-β1), assessed after 6 days Result:Inhibited TGF-β1-mediated proliferation of familial iPAH PASMCs at an IC50 of 295 nM.
-
In VivoSB525334 (3-30 mg/kg; p.o.; daily from days 17 to 35) significantly reverses pulmonary arterial pressure in a rat model of pulmonary arterial hypertension (PAH). Animal Model:Adult male Sprague-Dawley rats (MCT rat model of pulmonary hypertension)Dosage:3, 30 mg/kg Administration:Oral administration; daily from days 17 to 35 Result:Reduced the proportion of fully muscularized vessels to 28% at 3 mg/kg and returned fully muscularized vessel distribution beyond that seen at day 17 and approaching the phenotype observed in saline-exposed controls at 30 mg/kg.
-
SynonymsSB-525334 | SB525334
-
PathwayTGF-beta/Smad
-
TargetTGFBR
-
RecptorTGFβR1(ALK5)|ALK5|ALK4
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number356559-20-1
-
Formula Weight343.4249
-
Molecular FormulaC21H21N5
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 46 mg/mL
-
SMILESCC1=CC=CC(C2=C(C3=CC=C4N=CC=NC4=C3)N=C(C(C)(C)C)N2)=N1
-
Chemical NameQuinoxaline, 6-[2-(1,1-dimethylethyl)-5-(6-methyl-2-pyridinyl)-1H-imidazol-4-yl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Grygielko ET, et al. J Pharmacol Exp Ther. 2005 Jun;313(3):943-51.
2. Laping NJ, et al. Clin Cancer Res. 2007 May 15;13(10):3087-99.
3. Thomas M, et al. Am J Pathol. 2009 Feb;174(2):380-9.
4. Kim YJ, et al. Anticancer Res. 2012 Mar;32(3):799-806.
molnova catalog



related products
-
Disitertide
Disitertide (P144) is a TGF-β1 antagonist peptide.
-
Epimedin C
Epimedin C was metabolized via desugarization, dehydrogenation, hydrogenation, dehydroxylation, hydroxylation, demethylation and glucuronidation pathways in vivo.
-
LY2157299
LY2157299 (Galunisertib) is a potent, specific inhibitor of TGF-β receptor I kinase ((TGF-βRI) with IC50 of 56 nM.